Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TXAC - Therapeutics Acquisition Corp. Class A

Previous close
13
13.000   100.000%

Share volume: 0
Last Updated: Thu 06 Aug 2020 10:00:01 PM CEST
Financial Conglomerates: 0.01%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
87%
Profitability 93%
Dept financing 43%
Liquidity 60%
Performance 100%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$13.00
P/E Ratio 
N/A
DAY RANGE
$13.00 - $13.00
EPS 
$0.00
52 WEEK RANGE
$11.11 - $21.44
52 WEEK CHANGE
$7.82
MARKET CAP 
197.418 M
YIELD 
N/A
SHARES OUTSTANDING 
15.186 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$15,059
AVERAGE 30 VOLUME 
$58,165
Company detail
CEO: Peter Kolchinsky
Region: US
Website:
Employees: 0
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Financial Conglomerates
Sector: Finance

Therapeutics Acquisition Corp. is a blank check company with a purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Peter Kolchinsky and Matthew Hammond on April 15, 2020 and is headquartered in Boston, MA.

Recent news